<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507402</url>
  </required_header>
  <id_info>
    <org_study_id>R1033-HV-1107</org_study_id>
    <nct_id>NCT01507402</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess
      the safety and tolerability of Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786) in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of TEAEs</measure>
    <time_frame>Day 1 to Day 113</time_frame>
    <description>The primary endpoint in the study is the incidence and severity of TEAEs (Treatment Emergent Adverse Events) in subjects treated with REGN1033 or placebo, reported from the time of administration of study drug on day 1 (baseline) to completion of the study (day 113).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration</measure>
    <time_frame>Baseline to End of Study (Day 113)</time_frame>
    <description>To characterize the pharmacokinetic (PK) profile (i.e. serum concentration) of IV and SC doses of REGN1033.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline to End of Study (Day 113)</time_frame>
    <description>To assess the potential for immunogenicity following IV and SC doses of REGN1033.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 1 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 2 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 3 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 4 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 5 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 6 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 7 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 3 (Participants &gt; 65 to ≤ 85 yrs old)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen 9 (Participants 18 to ≤ 65 yrs old)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1033(SAR391786)</intervention_name>
    <description>Administration method A</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN1033(SAR391786)</intervention_name>
    <description>Administration method B</description>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>(inactive substance)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_label>Cohort 8</arm_group_label>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and postmenopausal or surgically sterile females

          2. Body mass index (BMI) between 18 and 30 kg/m2 inclusive

          3. Willing and able to return for all clinic visits and complete all study-related
             procedures

          4. Able to read and understand, and willing to sign the ICF

        Exclusion Criteria:

          1. Significant concomitant illness or history of significant illness such as, but not
             limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine,
             metabolic or lymphatic disease that would adversely affect the subject's participation
             in this study

          2. History of muscle neoplasms such as rhabdomyoma, rhabdomyosarcoma, leiomyoma,
             leiomyosarcoma or uterine fibroid tumors

          3. History of muscular dystrophy, myositis, and other primary diseases of skeletal muscle

          4. History of heart diseases including but not limited to coronary heart disease
             with/without history of myocardial infarction, chronic or acute heart failure, or
             cardiac arrhythmia, valvular heart disease or cardiac hypertrophy. Subjects taking
             prophylactic aspirin are excluded from the study and should not discontinue taking
             prophylactic aspirin to participate in the study

          5. History of systemic hypertension or use of concomitant medications to treat
             hypertension, or history of pulmonary hypertension

          6. History of diabetes mellitus or gestational diabetes or use of concomitant medications
             for treatment of these

          7. Recent use of androgenic steroids

          8. Unexplained creatine phosphokinase (CPK) levels &gt;3X upper limit of normal.

          9. Any medical or psychiatric condition which, in the opinion of the investigator, would
             place the subject at risk, interfere with participation in the study or interfere with
             the interpretation of the study results

         10. Women of childbearing potential (not surgically sterile or amenorrheic for at least
             twelve months if postmenopausal)

         11. Onset of a new exercise routine or major change to a previous exercise or diet routine
             within 4 weeks prior to screening. Subjects must be willing to maintain his/her
             previous level of exercise for the duration of the study

         12. Known history of seropositivity to human immunodeficiency virus (HIV) antibody;
             hepatitis B surface antigen or hepatitis C antibody (HCV) associated with a positive
             HCV RNA polymerase chain reaction at the screening visit

         13. Positive urine drug test results during screening or history of drug or alcohol abuse
             within a year prior to the screening visit

         14. Any hospitalization within 60 days prior to the screening visit

         15. Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives, whichever is longer, of the
             investigational drug, prior to the screening visit

         16. History of a hypersensitivity reaction to doxycycline or to other tetracycline drugs

         17. Previous exposure to any biological therapeutic agent, excepting vaccines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>November 12, 2012</last_update_submitted>
  <last_update_submitted_qc>November 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

